FZ002

FZ002 refers to two distinct investigational drugs in current development: 1. **FZ002 by Fzata** is a first-in-class live biotherapeutic yeast genetically engineered to express a tetraspecific anti-toxin for *Clostridioides difficile* (C. difficile) infection. It is designed for oral delivery and acts directly in the gastrointestinal tract, neutralizing both C. difficile toxins A and B while providing probiotic activity without promoting antibiotic resistance. The drug leverages Fzata’s Bioengineered Probiotic Yeast Medicines (BioPYM) platform, functioning as a “micro-factory” that produces therapeutic biologics *in situ* within the GI tract[1][4][7]. Its primary indication is prevention and treatment of recurrent C. difficile infection. 2. **FZ 002 / FZ002-037 by Guangzhou Fermion Technology** is an orally administered small-molecule non-opioid analgesic developed for pain management, particularly targeting somatostatin receptor subtype 4 (SSTR4). This highly selective SSTR4 agonist primarily acts on peripheral pain pathways to provide analgesia without central nervous system side effects or addiction potential[3][5]. It has completed Phase I trials in China with plans for Phase II studies targeting diabetic peripheral neuropathic pain and potentially other chronic or acute pain conditions.